IQVIA HOLDINGS INC.

(IQV)
  Report
Delayed Nyse  -  04:03 2022-08-17 pm EDT
240.62 USD   -1.67%
08/15IQVIA Wins Snowflake's “Marketplace Healthcare and Life Sciences Partner of the Year” Award
BU
08/11Cipher Pharmaceuticals Reports Q2 Diluted EPS of US$0.08
MT
08/08GlaxoSmithKline, IQVIA Introduce Vaccination Data Tracker
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Piper Sandler Lifts IQVIA Holdings to Overweight From Neutral, Price Target to $255 From $231

04/29/2022 | 05:30am EDT


© MT Newswires 2022
All news about IQVIA HOLDINGS INC.
08/15IQVIA Wins Snowflake's “Marketplace Healthcare and Life Sciences Partner of the Y..
BU
08/11Cipher Pharmaceuticals Reports Q2 Diluted EPS of US$0.08
MT
08/08GlaxoSmithKline, IQVIA Introduce Vaccination Data Tracker
MT
07/29IQVIA HOLDINGS INC. : Change in Directors or Principal Officers (form 8-K)
AQ
07/29IQVIA Holdings Inc. Announces Executive Changes
CI
07/27Dr. Reddy's Launches Generic Version of Myeloma Drug Velcade in US
MT
07/26China Accepts Sihuan Pharmaceutical Unit's Marketing for Breast Cancer Injection
MT
07/22IQVIA HOLDINGS INC. Management's Discussion and Analysis of Financial Condition and Re..
AQ
07/22Barclays Adjusts Price Target on IQVIA Holdings to $255 from $236, Keeps Overweight Rat..
MT
07/22Morgan Stanley Adjusts IQVIA Holdings' Price Target to $260 from $255, Keeps Overweight..
MT
More news
Analyst Recommendations on IQVIA HOLDINGS INC.
More recommendations
Financials (USD)
Sales 2022 14 500 M - -
Net income 2022 1 221 M - -
Net Debt 2022 10 874 M - -
P/E ratio 2022 38,3x
Yield 2022 -
Capitalization 45 640 M 45 640 M -
EV / Sales 2022 3,90x
EV / Sales 2023 3,54x
Nbr of Employees 83 000
Free-Float 72,2%
Chart IQVIA HOLDINGS INC.
Duration : Period :
Iqvia Holdings Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends IQVIA HOLDINGS INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 20
Last Close Price 244,71 $
Average target price 267,72 $
Spread / Average Target 9,40%
EPS Revisions
Managers and Directors
Ari Bousbib Chairman, President & Chief Executive Officer
Ronald Earl Bruehlman Chief Financial Officer & Executive Vice President
Karl Guenault Chief Information Officer & Senior Vice President
Jeffrey A. Spaeder Chief Medical & Scientific Officer
Costa Panagos President-Research & Development Solutions
Sector and Competitors
1st jan.Capi. (M$)
IQVIA HOLDINGS INC.-13.27%45 640
MODERNA, INC.-33.87%65 706
LONZA GROUP AG-26.68%43 587
SEAGEN INC.10.30%31 450
ALNYLAM PHARMACEUTICALS, INC.34.54%27 384
CELLTRION, INC.7.07%22 159